LANOVA MEDICINES
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
LANOVA MEDICINES
Industry:
Health Care Medical Pharmaceutical
Founded:
2019-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.lanovamedicines.com
Status:
Active
Contact:
021-68889618
Email Addresses:
[email protected]
Total Funding:
84.43 M USD
Technology used in webpage:
Alibaba HiChina DNS
Similar Organizations
ChoiPharm
ChoiPharm is a high-tech enterprise specializing in drug research and development.
Hope Medicine
Hope Medicine is a science-driven clinical stage biopharmaceutical company
JINRUI FOUNDATION
JINRUI FOUNDATION is a drug research and development company.
Purple Biotech
Purple Biotech is an innovative biopharmaceutical drug development company.
Medicilon
Medicilon is a biomedical research and development service company.
Orbiepharm
Orbiepharm is a pet medicine and western medicine research and development company.
PegBio
PegBio is a Chinese innovative drug developer.
Portal Instruments
Portal Instruments is an early stage company that offers medical device.
Sciwind Biosciences
Sciwind Biosciences is a drug research and development company for metabolic diseases.
Sho Engineering
Sho Engineering is a company focusing on planning, research and product development.
Shouyao Holding
Shouyao Holding is a tumor and diabetes drug research and development company.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Investors List
Summer Capital
Summer Capital investment in Series B - LaNova Medicines
Qiming Venture Partners
Qiming Venture Partners investment in Series B - LaNova Medicines
Shanghai Biomedical Industrial Equity Investment Fund
Shanghai Biomedical Industrial Equity Investment Fund investment in Series B - LaNova Medicines
Asymchem Laboratories (Tianjin)
Asymchem Laboratories (Tianjin) investment in Series A - LaNova Medicines
Qiming Venture Partners
Qiming Venture Partners investment in Series A - LaNova Medicines
Official Site Inspections
http://www.lanovamedicines.com
- Host name: 47.96.194.197
- IP address: 47.96.194.197
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "LaNova Medicines"
Home-LaNova Medicines
Established since 2019 in Shanghai, China, LaNova Medicines has emerged as a clinical-stage biotechnology company committed to discovering and developing innovative biologic drugs …See details»
About Us-LaNova Medicines
Founded in 2019, LaNova Medicines is a research-driven biotech company dedicated to discovering and developing antibody-based cancer treatments. Our founders envisioned transforming global cancer care. Under the mission "Care …See details»
LaNova Medicines - Crunchbase Company Profile & Funding
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor …See details»
Our Science-LaNova Medicines
Leveraging extensive experience in everything from early target validation and antibody engineering to downstream translational medicine, LaNova has built a robust antibody …See details»
LaNova Medicines - LinkedIn
Founded in 2019 in Shanghai, China, LaNova Medicines is a clinical-stage biotechnology company committed to the discovery and development of novel biologic drugs for cancer treatment.See details»
LaNova Medicines - Overview, News & Similar companies
View LaNova Medicines (www.lanovamedicines.com) location in Shanghai, China , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
LaNova Medicines Announces Global Exclusive License ... - BioSpace
May 12, 2023 · LaNova Medicines Ltd. (“LaNova Medicines”) announced today it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305, a pre …See details»
LaNova Medicines Announces Global Exclusive License Agreement …
May 12, 2023 · LaNova Medicines is eligible to receive an upfront and near-term payments of up to $55 million and additional development and commercial milestone payments of up to $545 …See details»
LaNova Medicines - VentureRadar
Website: https://www.lanovamedicines.com/en Develops antibody-based cancer treatments, aiming to transform global cancer care through innovation, guided by excellence, persistence, …See details»
LaNova Medicines Announces Global Exclusive License Agreement …
May 12, 2023 · LaNova Medicines is eligible to receive an upfront and near-term payments of up to $55 million and additional development and commercial milestone payments of up to $545 …See details»
公司概况-礼新医药官网 - lanovamedicines.com
礼新医药是一家立足中国，面向全球的临床阶段创新药研发公司，由生物医药业界资深人士创立。 公司创始以来，始终以“礼敬生命，致力创新”为使命，以开发优质药物，满足患者需求为愿景；贯彻“卓越、坚持、诚信、合作”的价值观。 公司 …See details»
LaNova Medicines Announces Global Exclusive License Agreement …
SHANGHAI, May 12, 2023 /PRNewswire/ -- LaNova Medicines Ltd. ("LaNova Medicines") announced today it has entered into an exclusive license agreement with AstraZeneca …See details»
LaNova Medicines - PitchBook
Developer of pharmaceutical technology and biotechnology focusing on tumor immunity and tumor microenvironment therapy. The company is mainly engaged in the research and …See details»
LaNova Medicines and AstraZeneca sign licence deal for LM-305
May 15, 2023 · Chinese biotech company LaNova Medicines and AstraZeneca have entered an exclusive licence deal for La Nova’s LM-305. Peptide libraries are a powerful tool in biological …See details»
Join Us-LaNova Medicines
LaNova is committed to building an excellent learning organization Providing personal career improvement and development opportunities, and fully supporting LaNova employees at …See details»
LaNova Medicines (Zhejiang) Co., Ltd.
Clinical researchers and pharmaceutical companies continue to seek innovative solutions that offer enhanced efficacy and reduced side effects. Among the ongoing significant …See details»
LaNova Medicines and Turning Point Therapeutics Enter into …
Jul 5, 2022 · LaNova Medicines announced that it has entered into an exclusive license agreement with Turning Point Therapeutics (NASDAQ: TPTX) to develop and commercialize …See details»
LaNova News-LaNova Medicines
LaNova Medicines Completes USD 42 Million Series C1 Financing to Accelerate Clinical Progress and Innovation Platform DevelopmentSee details»
LaNova Medicines Ltd. (礼新医药科技（上海）有限公司) - 药物管 …
To assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) or optimal biological dose (OBD) and the recommended phase 2 dose (RP2D) for LM-299 in subjects with …See details»
Pipeline-LaNova Medicines
LX-TDuo™ Bispecific Antibody Platform.See details»